Peptimmune: Experienced Leadership

About Our Company

Our Headquarters
Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP™ Technology to design peptides and peptide mixtures.

Learn more

Meet Our Team

Kristen Nicholas

Kristen Nicholas

Office Manager and Executive Assistant
Kristen Nicholas joined Peptimmune in 2008 as the office manager/executive assistant. For seven years, Kristen was an investment administrative assistant at Cambridge Trust Company. She has an AS in Retail Management…

Learn more

Latest News

Peptimmune Completes Phase I

We've completed our first clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics…

Announcing Series D Financing

Announcing our completion of the first close of $8.2 million of a Series D preferred stock offering with its investor…

View all

Upcoming Events

Peptimmune Presentation at FOCIS

Dr. Joseph Kovalchin, senior scientist, will present information on PI-2301 peptide copolymer for the treatment of multiple sclerosis at the Federation of Clinical Immunology Societies (FOCIS) 2008 meeting in Boston, MA.

View all

Pipeline

PI-2301 is a second-generation peptide copolymer that has superior efficacy and convenience profile compared to Copaxone® for the treatment of Multiple Sclerosis.

Learn more

Platform Technology

DEEP™ Technology - Directed Expansion of an Epitope through Permutating native or novel peptide sequences

Antibodies | Novel Therapeutics | Vaccines

Learn more

Patient Information

Multiple Sclerosis Trial Notice - Peptimmune is now Enrolling Patients in France with Secondary Progressive Multiple Sclerosis (SPMS)

Learn more